PABLO MARIA ALBERTO POMERANTZEFF

(Fonte: Lattes)
Índice h a partir de 2011
15
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Cardio-Pneumologia, Faculdade de Medicina - Docente
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina
LIM/11 - Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação, Hospital das Clínicas, Faculdade de Medicina - Líder
LIM/65, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Colaboração internacional: Bélgica ×

Resultados de Busca

Agora exibindo 1 - 2 de 2
  • article 4 Citação(ões) na Scopus
    Cardiovascular findings in Williams-Beuren Syndrome: Experience of a single center with 127 cases
    (2022) HONJO, Rachel Sayuri; MONTELEONE, Vanessa Figueiredo; AIELLO, Vera Demarchi; WAGENFUHR, Jaqueline; ISSA, Victor Sarli; POMERANTZEFF, Pablo Maria Alberto; FURUSAWA, Erika Arai; ZANARDO, Evelin Aline; KULIKOWSKI, Leslie Domenici; BERTOLA, Debora Romeo; KIM, Chong Ae
    Williams-Beuren syndrome (WBS) is a rare, microdeletion syndrome characterized by facial dysmorphisms, intellectual disability, a friendly personality, cardiovascular and other abnormalities. Cardiovascular defects (CVD) are among the most prevalent characteristics in WBS, being supravalvular aortic stenosis (SVAS) the most frequent, followed by peripheral pulmonary stenosis (PPS). A comprehensive retrospective review of medical records of 127 patients with molecular diagnosis of WBS, in a period of 20 years, was done to evaluate the incidence, the natural history of cardiovascular disease, and the need for surgical intervention, including heart transplantation (HT). A total of 94/127 patients presented with CVD. Of these 94 patients, 50% presented with SVAS and 22.3% needed heart surgery and/or cardiac catheterization including one that required HT due to severe SVAS-related heart failure at 19 years of age. The patient died in the postoperative period due to infectious complications. Cardiovascular problems are the major cause of sudden death in patients with WBS, who have a significantly higher mortality risk associated with surgical interventions. There is a higher risk for anesthesia-related adverse events and for major adverse cardiac events following surgery. End-stage heart failure due to myocardial ischemia has been described in WBS patients and it is important to consider that HT can become their only viable option. To our knowledge, the case mentioned here is the first HT reported in an adolescent with WBS. HT can be a viable therapeutic option in WBS patients with adequate evaluation, planning, and a multidisciplinary team to provide the required perioperative care and follow-up.
  • article 205 Citação(ões) na Scopus
    Vasopressin versus Norepinephrine in Patients with Vasoplegic Shock after Cardiac Surgery The VANCS Randomized Controlled Trial
    (2017) HAJJAR, Ludhmila Abrahao; VINCENT, Jean Louis; GALAS, Filomena Regina Barbosa Gomes; RHODES, Andrew; LANDONI, Giovanni; OSAWA, Eduardo Atsushi; MELO, Renato Rosa; SUNDIN, Marcia Rodrigues; GRANDE, Solimar Miranda; GAIOTTO, Fabio A.; POMERANTZEFF, Pablo Maria; DALLAN, Luis Oliveira; FRANCO, Rafael Alves; NAKAMURA, Rosana Ely; LISBOA, Luiz Augusto; ALMEDIA, Juliano Pinheiro de; GERENT, Aline Muller; SOUZA, Dayenne Hianae; GAIANE, Maria Alice; FUKUSHIMA, Julia Tizue; PARK, Clarice Lee; ZAMBOLIM, Cristiane; FERREIRA, Graziela Santos Rocha; STRABELLI, Tania Mara; FERNANDES, Felipe Lourenco; CAMARA, Ligia; ZEFERINO, Suely; SANTOS, Valter Garcia; PICCIONI, Marilde Albuquerque; JATENE, Fabio Biscegli; AULER JR., Jose Otavio Costa; KALIL FILHO, Roberto
    Background: Vasoplegic syndrome is a common complication after cardiac surgery and impacts negatively on patient outcomes. The objective of this study was to evaluate whether vasopressin is superior to norepinephrine in reducing postoperative complications in patients with vasoplegic syndrome. Methods: This prospective, randomized, double-blind trial was conducted at the Heart Institute, University of Sao Paulo, Sao Paulo, Brazil, between January 2012 and March 2014. Patients with vasoplegic shock (defined as mean arterial pressure less than 65 mmHg resistant to fluid challenge and cardiac index greater than 2.2 l.min(-1).m(-2)) after cardiac surgery were randomized to receive vasopressin (0.01 to 0.06 U/min) or norepinephrine (10 to 60 mu g/min) to maintain arterial pressure. The primary endpoint was a composite of mortality or severe complications (stroke, requirement for mechanical ventilation for longer than 48 h, deep sternal wound infection, reoperation, or acute renal failure) within 30 days. Results: A total of 330 patients were randomized, and 300 were infused with one of the study drugs (vasopressin, 149; norepinephrine, 151). The primary outcome occurred in 32% of the vasopressin patients and in 49% of the norepinephrine patients (unadjusted hazard ratio, 0.55; 95% CI, 0.38 to 0.80; P = 0.0014). Regarding adverse events, the authors found a lower occurrence of atrial fibrillation in the vasopressin group (63.8% vs. 82.1%; P = 0.0004) and no difference between groups in the rates of digital ischemia, mesenteric ischemia, hyponatremia, and myocardial infarction. Conclusions: The authors' results suggest that vasopressin can be used as a first-line vasopressor agent in postcardiac surgery vasoplegic shock and improves clinical outcomes.